NEW YORK (GenomeWeb News) — Indiana-based start-up Kylin Pharmaceuticals has licensed the rights to use more than 12 RNAi-related patents from the Purdue Research Foundation to develop drugs, the Foundation said today.
Kylin has received start-up capital from the Indiana venture group IN-vivo Ventures, and from the Research Triangle Park, NC-based Golden Pine Ventures. The company initially plans to focus its efforts on developing therapeutics for cancer, and for viral diseases such as AIDS later.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The New York Times reports that genetic testing has uncovered unfaithful penguins at a Utah aquarium.

Cancer researcher loses funding under new Wellcome Trust anti-bullying policies, the Guardian reports.

In Science this week: International Wheat Genome Sequencing Consortium publishes the bread wheat cultivar Chinese Spring reference genome, and more.

At his FDA Law Blog, Jeffrey Gibbs discusses FDA's technical assistance for the draft Diagnostic Accuracy and Innovation Act.